-

Memorial Sloan Kettering Cancer Center Extends Allscripts Sunrise™ Agreement

CHICAGO--(BUSINESS WIRE)--Allscripts Healthcare Solutions (NASDAQ: MDRX) today announced that Memorial Sloan Kettering Cancer Center (MSK), has extended its engagement with Allscripts Sunrise™ through 2026.

Allscripts Sunrise is an integrated electronic health record that can connect all aspects of care. As an evidence-based single platform, Sunrise has integrated analytics that can support core care venues across the enterprise.

“The Allscripts Sunrise platform has been a key component in our clinical platform for two decades,” said Memorial Sloan Kettering Cancer Center’s Chief Operating Officer, Kathryn Martin. “We look forward to continued collaboration with the Health IT company, working to meet the needs of our clinicians and, most importantly, our patients.”

“We’re honored to continue our work with Memorial Sloan Kettering Cancer Center, the largest and oldest private cancer center in the world,” said Allscripts CEO Paul Black. “Our more than 20-year relationship has helped many patients within the cancer community receive world-class care and we’re certain that the cancer center’s extension of its Sunrise engagement will be the right fit for its future success.”

About Allscripts

Allscripts (NASDAQ: MDRX) is a leader in healthcare information technology solutions that advance clinical, financial and operational results. Our innovative solutions connect people, places and data across an Open, Connected Community of Health™. Connectivity empowers caregivers and consumers to make better decisions, delivering better care for healthier populations. To learn more, visit www.allscripts.com, Twitter, YouTube and It Takes A Community: The Allscripts Blog.

© 2020 Allscripts Healthcare, LLC and/or its affiliates. All Rights Reserved.

Allscripts, the Allscripts logo, and other Allscripts marks are trademarks of Allscripts Healthcare, LLC and/or its affiliates. All other products are trademarks of their respective holders, all rights reserved. Reference to these products is not intended to imply affiliation with or sponsorship of Allscripts Healthcare, LLC and/or its affiliates.

 

Contacts

For more information contact:
Investors:
Stephen Shulstein
312-386-6735
Stephen.Shulstein@allscripts.com

Media:
Concetta Rasiarmos
312-447-2466
concetta.rasiarmos@allscripts.com

Allscripts

NASDAQ:MDRX

Release Versions
Hashtags

Contacts

For more information contact:
Investors:
Stephen Shulstein
312-386-6735
Stephen.Shulstein@allscripts.com

Media:
Concetta Rasiarmos
312-447-2466
concetta.rasiarmos@allscripts.com

More News From Allscripts

Veradigm Announces Updated Presentation Time for Upcoming Investor Conference

CHICAGO--(BUSINESS WIRE)--Veradigm® (OTCMKTS: MDRX), a leading provider of clinical and revenue cycle solutions for independent practices, announced today that it will now present at the 2026 Jefferies Healthcare Services and Technology Conference on September 15th at 3:35PM CT. A live webcast of the fireside chat will be available at the Veradigm investor relations website. About Veradigm® Veradigm has a proven history of delivering clinical and revenue cycle solutions that help independent pr...

Veradigm to Participate in Two Upcoming Investor Conferences

CHICAGO--(BUSINESS WIRE)--Veradigm® (OTCMKTS: MDRX), a leading provider of clinical and revenue cycle solutions for independent practices, announced today that management will be participating in the following investor conferences in September. 2026 Jefferies Healthcare Services and Technology Conference (Nashville, September 15, 2026) Don Trigg, Chief Executive Officer, and Christian Greyenbuhl, Chief Financial Officer, will hold one-on-one meetings and participate in a fireside chat on Tuesda...

Veradigm Files 2023 and 2024 Form 10-K

CHICAGO--(BUSINESS WIRE)--Veradigm® (OTCMKTS: MDRX), a leading provider of clinical and revenue cycle solutions for independent practices, announced today the filing of its comprehensive Annual Report on Form 10-K for the years ended December 31, 2023 and 2024 (the “2023 and 2024 Form 10-K”) with the Securities and Exchange Commission (“SEC”). “In our previous shareholder update, I framed a critical must-do to get current and stay current on our SEC filings. Today marks a major milestone in tha...
Back to Newsroom